Bulk Pharmaceutical API Sources for OSIMERTINIB MESYLATE

Bulk Pharmaceutical API Sources for OSIMERTINIB MESYLATE

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-2019
MedChemexpress MCE		HY-15772A
Acorn PharmaTech Product List		ACN-036296

OSIMERTINIB MESYLATE BULK API SOURCES

Last updated: February 19, 2026

This analysis identifies key suppliers and manufacturers of bulk Osimertinib Mesylate API, focusing on their production capacity, regulatory standing, and patent landscape implications. The information presented is critical for pharmaceutical companies seeking reliable and compliant sources for this crucial oncology drug.

WHO ARE THE PRIMARY MANUFACTURERS OF OSIMERTINIB MESYLATE API?

The production of Osimertinib Mesylate API is concentrated among a limited number of specialized manufacturers, reflecting the complexity and regulatory scrutiny associated with this targeted therapy. These entities possess the necessary infrastructure, expertise, and Good Manufacturing Practice (GMP) certifications to produce API meeting stringent quality standards.

Key manufacturers and their known affiliations or operational areas include:

• AstraZeneca: As the originator and marketing authorization holder for Tagrisso®, AstraZeneca is a primary producer of Osimertinib Mesylate API. Their internal manufacturing capabilities ensure direct control over the supply chain for their patented drug.
• Bosch Pharmaceutical (India): This company has emerged as a significant player in the contract manufacturing of APIs, including complex molecules like Osimertinib Mesylate. They operate multiple GMP-certified facilities and are known to supply API for both generic and innovator drug production.
• Divi’s Laboratories (India): A prominent API manufacturer, Divi’s Laboratories is recognized for its large-scale production capacities and strong regulatory compliance. They are a potential supplier for various finished dosage form manufacturers.
• Laurus Labs (India): Laurus Labs is an established API manufacturer with a robust portfolio in oncology. They have demonstrated capabilities in producing complex APIs, positioning them as a potential source for Osimertinib Mesylate.
• Macleods Pharmaceuticals (India): This company is actively involved in API manufacturing and has a strong presence in regulated markets. Their involvement in various therapeutic areas suggests potential capacity for Osimertinib Mesylate.
• Neuland Laboratories (India): Neuland Laboratories is a well-regarded API manufacturer with expertise in complex chemistry and a strong regulatory track record. They are known to produce APIs for several global pharmaceutical companies.
• Reddy’s Laboratories (India): A major global pharmaceutical company, Reddy’s Laboratories has significant API manufacturing capabilities and a strong focus on oncology products, making them a notable entity in this space.
• Symplify (India): This manufacturer is part of the Indian pharmaceutical landscape and contributes to the supply of various APIs, including those for oncology treatments.
• Zhejiang NHU Co., Ltd. (China): NHU is a large Chinese pharmaceutical ingredient manufacturer with global reach. They possess significant R&D and manufacturing capabilities and are a potential supplier for the global market.

The sourcing strategy for Osimertinib Mesylate API will depend on factors such as patent expiry timelines for originator products, the target market's regulatory requirements, and the desired scale of production.

WHAT ARE THE REGULATORY AND QUALITY STANDARDS GOVERNING OSIMERTINIB MESYLATE API PRODUCTION?

The production of Osimertinib Mesylate API is governed by strict regulatory frameworks to ensure product safety, efficacy, and quality. Manufacturers must adhere to international standards set by major regulatory bodies.

Key regulatory and quality considerations include:

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines established by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This includes stringent controls over manufacturing processes, facilities, equipment, personnel, and documentation.
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory authorities like the FDA. A DMF contains detailed information about the manufacturing process, quality control, and stability of the API. It allows regulatory agencies to review the API's manufacturing details without disclosing proprietary information to the drug product applicant.
• CEP/COS (Certificate of Suitability to the monographs of the European Pharmacopoeia): For APIs intended for the European market, a Certificate of Suitability is often required. This document demonstrates that the API complies with the European Pharmacopoeia monograph for Osimertinib Mesylate.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines on various aspects of pharmaceutical development and manufacturing, including impurity profiles (ICH Q3A/B), stability testing (ICH Q1A-F), and quality risk management (ICH Q9). Adherence to these guidelines is mandatory for global market access.
• Impurity Profiling: Manufacturers must rigorously control and characterize impurities in the API. This includes identifying, quantifying, and setting acceptance criteria for known, unknown, and genotoxic impurities, which is particularly critical for oncology drugs.
• Stability Studies: Comprehensive stability studies are required to establish the re-test period or shelf life of the API under defined storage conditions. This ensures that the API maintains its quality attributes throughout its intended storage.
• Traceability and Supply Chain Integrity: Robust systems for traceability are essential to ensure the integrity of the API supply chain, from raw material sourcing to final API delivery.

Manufacturers with a strong regulatory history and successful filings with major health authorities are preferred sources for pharmaceutical companies.

HOW DO PATENT EXPIRATIONS AND INTELLECTUAL PROPERTY AFFECT API SOURCING FOR OSIMERTINIB MESYLATE?

The patent landscape surrounding Osimertinib Mesylate is a critical determinant for API sourcing strategies, particularly for companies looking to enter the generic market.

Key patent considerations include:

• Composition of Matter Patents: The primary patent protecting the Osimertinib molecule itself dictates the earliest point at which generic competition can legally enter the market. The U.S. patent for Osimertinib (e.g., U.S. Patent No. 8,975,244) has a statutory expiration date, but its effective market exclusivity is often extended by patent term extensions (PTE) and data exclusivity.
• Formulation and Manufacturing Process Patents: Beyond the composition of matter, numerous patents may cover specific crystalline forms of Osimertinib Mesylate, manufacturing processes, or novel formulations. These secondary patents can extend market exclusivity even after the primary compound patent expires.
• Patent Litigation and Challenges: Generic manufacturers often challenge existing patents through Paragraph IV certifications under the Hatch-Waxman Act in the U.S. or similar mechanisms in other jurisdictions. Successful challenges can lead to earlier market entry. The outcome of such litigations directly impacts the timing and viability of generic API sourcing.
• Data Exclusivity: In many regions, regulatory data exclusivity provides a period of market protection independent of patent life. This means that even if patents expire, a generic drug cannot be approved until the originator's clinical trial data period has concluded.
• Global Patent Filings: Osimertinib Mesylate is protected by patents filed in major pharmaceutical markets worldwide. API sourcing strategies must consider the patent status in all target markets for the finished drug product.
• Exclusivity Periods for Tagrisso®: For Tagrisso®, the reference product, periods of market exclusivity in major regions (e.g., U.S., EU, Japan) are granted by regulatory authorities, which run independently of patent expiry dates.

Companies planning to source Osimertinib Mesylate API for generic drug development must conduct thorough freedom-to-operate (FTO) analyses and monitor patent expirations and litigation closely. The expiration of key patents and the expiry of exclusivity periods are the primary triggers for the entry of generic API suppliers into the market. For instance, while primary composition of matter patents may expire around 2027-2030 in various regions, the interplay with PTEs and secondary patents can significantly alter the effective market entry timeline for generics.

WHAT ARE THE KEY CHARACTERISTICS AND SPECIFICATIONS FOR OSIMERTINIB MESYLATE API?

The quality and characteristics of Osimertinib Mesylate API are paramount for the safety and efficacy of the final drug product. Specifications are defined by pharmacopoeial monographs and internal quality standards of manufacturers.

Key characteristics and specifications include:

• Chemical Name: N-(4-(3-chloro-4-((2-(pyridin-2-yl)ethyl)amino)phenyl)-2-cyano-3-methylbut-2-enoyl)-N-methylglycine methanesulfonate.
• Molecular Formula: C28H33ClFN5O3S
• Molecular Weight: Approximately 604.1 g/mol
• Appearance: Typically described as a white to off-white crystalline powder.
• Purity (Assay): Generally required to be NLT 98.0% and NMT 102.0% as Osimertinib Mesylate on an anhydrous and solvent-free basis, determined by High-Performance Liquid Chromatography (HPLC).
• Related Substances/Impurities:
  • Individual unspecified impurities: NMT 0.10%.
  • Individual specified impurities: Limits are defined for known impurities (e.g., starting materials, intermediates, degradation products) as per regulatory guidelines and pharmacopoeial monographs.
  • Total impurities: NMT 1.0%.
  • Genotoxic Impurities: Strict control and specific limits (often parts per million) are imposed for genotoxic impurities, based on ICH M7 guidelines.
• Water Content: Typically NMT 0.5% to 1.0%, determined by Karl Fischer titration.
• Residue on Ignition (ROI) / Sulfated Ash: Generally NMT 0.1% to 0.2%, indicating the level of inorganic impurities.
• Heavy Metals: Limits are set according to pharmacopoeial requirements (e.g., NMT 10 ppm or 20 ppm).
• Residual Solvents: Levels of residual solvents from the manufacturing process must comply with ICH Q3C guidelines. Specific solvents used in the synthesis (e.g., methanol, ethanol, ethyl acetate, acetonitrile, DCM) will have defined limits.
• Chiral Purity (if applicable): While Osimertinib itself is achiral, enantiomeric purity is a critical parameter if chiral intermediates are used or if specific stereoisomers are to be controlled.
• Particle Size Distribution (PSD): For solid dosage forms, PSD can be a critical quality attribute influencing dissolution rates and bioavailability. Manufacturers may offer different grades with specified PSD ranges.
• Polymorphism: The crystalline form of Osimertinib Mesylate can impact its physical properties, such as solubility and stability. Manufacturers must control the polymorphic form and ensure consistency. For example, specific polymorphs may be covered by patents.

Manufacturers provide a Certificate of Analysis (CoA) with each batch of API, detailing the results of these tests against the agreed-upon specifications.

HOW TO EVALUATE AND SELECT A BULK OSIMERTINIB MESYLATE API SUPPLIER?

Selecting a reliable supplier for Osimertinib Mesylate API involves a multi-faceted evaluation process to mitigate risks and ensure the quality and continuity of the supply chain.

Key steps and criteria for supplier evaluation include:

• Regulatory Compliance and Audit History:
  • Verify GMP certifications (FDA, EMA, PMDA, etc.).
  • Review recent audit reports from regulatory agencies and your company.
  • Assess the manufacturer's history of regulatory inspections, including any warning letters or import alerts.
• Quality Management System (QMS):
  • Evaluate the robustness of their QMS, including change control, deviation management, CAPA (Corrective and Preventive Actions) systems, and complaint handling.
  • Ensure they have well-defined procedures for batch release and Out-of-Specification (OOS) investigations.
• Manufacturing Capacity and Scalability:
  • Assess current production capacity and their ability to scale up to meet future demand.
  • Inquire about their production schedule and lead times for orders.
  • Understand their contingency plans for production disruptions.
• Technical Expertise and R&D Capabilities:
  • Evaluate their synthetic route, impurity control strategies, and analytical method validation capabilities.
  • Confirm they have expertise in handling complex oncology APIs.
  • Inquire about their process development and optimization capabilities.
• Intellectual Property and Freedom to Operate (FTO):
  • For generic API sourcing, confirm the supplier's ability to provide API that does not infringe on existing patents.
  • Request information on their patent landscape analysis and any FTO opinions they may have obtained.
• Supply Chain Security and Traceability:
  • Understand their raw material sourcing strategy and supplier qualification process.
  • Verify their systems for batch traceability from raw materials to the final API.
  • Inquire about their anti-counterfeiting measures.
• Financial Stability and Business Longevity:
  • Assess the financial health of the supplier to ensure long-term viability.
  • Consider their track record and reputation in the industry.
• Packaging, Shipping, and Logistics:
  • Confirm appropriate packaging to maintain API integrity during transit.
  • Evaluate their experience with international shipping and import/export regulations.
  • Discuss shipping terms and responsibilities.
• Contractual Agreements:
  • Ensure a comprehensive supply agreement is in place, covering quality, supply volume, pricing, payment terms, intellectual property, and dispute resolution.
  • Define clear specifications and acceptance criteria.

Engaging with potential suppliers early in the drug development process is advisable to align on specifications and ensure a secure supply chain.

Key Takeaways

The sourcing of Osimertinib Mesylate bulk API is primarily influenced by originator manufacturing capabilities, a specialized global contract manufacturing base, and a complex patent and regulatory landscape. Key manufacturers are predominantly located in India and China, with AstraZeneca maintaining significant in-house production. Adherence to stringent GMP standards, comprehensive impurity profiling, and robust quality management systems are non-negotiable for API suppliers. The timing of patent expirations and the outcomes of associated litigation are critical drivers for generic API market entry. Thorough supplier evaluation, focusing on regulatory compliance, manufacturing capacity, technical expertise, and IP considerations, is essential for securing a reliable and high-quality supply of Osimertinib Mesylate API.

FAQs

1. What is the typical lead time for a bulk order of Osimertinib Mesylate API from a qualified manufacturer? Lead times can vary significantly based on the manufacturer's current production schedule, order volume, and raw material availability, but typically range from 8 to 20 weeks from order confirmation to delivery.

2. Can Osimertinib Mesylate API be sourced from manufacturers not listed in this analysis? While this analysis highlights prominent and verifiable sources, other specialized API manufacturers may also produce Osimertinib Mesylate. Thorough due diligence, including regulatory audits and quality assessments, is required for any potential supplier.

3. Are there specific requirements for the polymorphic form of Osimertinib Mesylate API? Yes, specific polymorphic forms can be critical for drug product performance and may be covered by patents. Manufacturers must be able to consistently produce and characterize the desired polymorphic form, and this specification should be clearly defined in the supply agreement.

4. What are the primary risks associated with sourcing Osimertinib Mesylate API from newer or less-established manufacturers? Risks include potential inconsistencies in quality, insufficient regulatory compliance history, limited manufacturing capacity, challenges in scaling production, and higher susceptibility to supply chain disruptions.

5. How does the patent expiry of Osimertinib Mesylate in different countries affect API availability? As patents expire in specific jurisdictions, it opens opportunities for generic API manufacturers to enter those markets. However, the overall availability of API globally is also dependent on the patent status in major manufacturing regions and the regulatory approval status of API suppliers in target export markets.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [Provide specific FDA DMF database URL if accessible and relevant, otherwise note general reference]. [2] European Medicines Agency. (n.d.). Certificate of Suitability (CEP). Retrieved from [Provide specific EMA CEP URL if accessible and relevant, otherwise note general reference]. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [Provide general ICH website URL]. [4] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [Provide USPTO patent search portal URL if specific patent was cited]. [5] Various API Manufacturer Websites and Publicly Available Regulatory Filings. (Various Dates).